S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Additional Paid In Capital
ÂĄ1.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Additional Paid In Capital
ÂĄ81.4B
CAGR 3-Years
15%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Additional Paid In Capital
ÂĄ27.5B
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Additional Paid In Capital
ÂĄ3.3B
CAGR 3-Years
95%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Additional Paid In Capital
ÂĄ3.5B
CAGR 3-Years
-1%
CAGR 5-Years
90%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
1.5B CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 1.5B CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
37%

Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 37% over the past three years .

Back to Top